Drug news
Onyx Pharma files carfilzomib at the FDA for Multiple Myeloma
The FDA has accepted a new drug application for carfilzomib from Onyx Pharmaceuticals. Onyx is seeking accelerated approval of carfilzomib, a next-generation proteasome inhibitor, as a treatment for patients with relapsed and refractory Multiple Myeloma. The application will be supported by progression-free survival data from the randomized controlled carfilzomib Phase III ASPIRE trial in relapsed multiple myeloma anticipated in early 2013. A review date has not yet been notified by the FDA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.